Продольное исследование тромбоцита циклическая АТФ в течение здоровой беременности и беременностей в опасности преэклампсии, страница 2

TI: Administration of granulocyte colony-stimulating factor to neutropenic low birth weight infants of mothers with preeclampsia.

TI: Назначение(воздействие) колониестимулирующего фактора гранулоцита нейтропеническим низким младенцам веса рождения матерей с преэклампсией.

AU: Makhlouf-RA; Doron-MW; Bose-CL; Price-WA; Stiles-AD

AD: Department of Pediatrics, University of North Carolina at Chapel Hill 27599-7596.

SO: J-Pediatr. 1995 Mar; 126(3): 454-6

AB: Nine low birth weight infants with neutropenia born to mothers with preeclampsia were treated with granulocyte-colony stimulating factor, 10 micrograms/kg intravenously, within 24 hours of birth and at 24-hour intervals for a maximum of three doses if neutropenia persisted. The absolute neutrophil count increased significantly in eight of the nine infants within 6 hours, and neutrophilia was sustained for at least 72 hours after administration of a single dose of granulocyte-colony stimulating factor.

Девять низких младенцев веса рождения с нейтропенией, несенной матерям с преэклампсией, леченной с колонией гранулоцита, стимулирующей фактор, 10 micrograms/kg внутривенно, в пределах 24 часов рождения и в 24-часовых интервалах для максимума трех доз, если нейтропения сохранилась. Абсолютный счет(граф) нейтрофила увеличился значительно в восьми из этих девяти младенцев в пределах 6 часов, и нейтрофиллез был поддержан в течение по крайней мере 72 часов после назначения(воздействия) единственной(отдельной) дозы колонии гранулоцита, стимулирующей фактор.

TI: Omega-3 fatty acids in maternal erythrocytes and risk of preeclampsia.

TI: omega-3 жирные кислоты в материнских эритроцитах и риске преэклампсии.

AU: Williams-MA; Zingheim-RW; King-IB; Zebelman-AM

AD: Center for Perinatal Studies, Swedish Medical Center/Seattle, WA 98114-0999, USA.

SO: Epidemiology. 1995 May; 6(3): 232-7

AB: Preeclampsia is a systemic disease characterized by diffuse endothelial dysfunction, increased peripheral vascular resistance, coagulation abnormalities, antioxidant deficiency, persistent elevations of maternal leukocyte-derived cytokines, and hyperlipidemia. Fish oil, rich in omega-3 polyunsaturated fatty acids, is known to reduce fasting and postprandial triglycerides and to decrease platelet and leukocyte reactivity; it may also decrease blood pressure. Additionally, omega-3 fatty acids may beneficially influence vessel wall characteristics and blood rheology. In light of the potential beneficial effects of dietary omega-3 fatty acids, we conducted a cross-sectional case-control study to examine the hypothesized exposure-effect relation between maternal dietary intake of marine omega-3 fatty acids and risk of preeclampsia. We measured polyunsaturated fatty acids in erythrocytes obtained from 22 preeclamptic women and 40 normotensive women; we measured polyunsaturated fatty acids as the percentage of total fatty acids from gas chromatography. We employed logistic regression procedures to estimate odds ratios (ORs) and 95% confidence intervals (CIs). After adjusting for confounders, women with the lowest levels of omega-3 fatty acids were 7.6 times more likely to have had their pregnancies complicated by preeclampsia as compared with those women with the highest levels of omega-3 fatty acids (95% CI = 1.4-40.6). A 15% increase in the ratio of omega-3 to omega-6 fatty acids was associated with a 46% reduction in risk of preeclampsia (OR = 0.54; 95% CI = 0.41-0.72). Low erythrocyte levels of omega-3 fatty acids and high levels of some omega-6 fatty acids, particularly arachidonic acid, appear to be associated with an increased risk of preeclampsia.